ScottJDiedeMDPhD

Pediatric Hematology & Oncology • North Wales, PA

Executive Director, Late Melanoma Global Development Lead, Merck Research Laboratories

Join to view full profile

Dr. Diede is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Diede's full profile

Already have an account?

Office
351 N. Sumneytown Pike
Mailstop UG4D-58
North Wales, PA 19454
Is this information wrong?

Education & Training

University of Washington School of MedicineFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of Washington School of MedicineResidency, Pediatrics, 2004 - 2005
University of Washington School of MedicineInternship, Pediatrics, 2003 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003
University of ChicagoPhD, Pathology, 2001
University of ChicagoBA, Chemistry, 1988 - 1992

Certifications & Licensure

PA State Medical License 2014 - 2016
WA State Medical License 2005 - 2015

Awards, Honors, & Recognition

Young Investigator Award Alex's Lemonade Stand for Childhood Cancer Research, 2010
Scholar St. Baldrick's Foundation, 2010
Basic Research Fellowship in memory of Emily Ann Dorfman American Brain Tumor Association, 2010
Scholar Hyundai Hope on Wheels, 2010
Young Investigator Award American Society of Clinical Oncology, 2008
Scholar Child Health Research Center, UWSOM, 2008
Special Alternative Pathway in Pediatric Hematology-Oncology American Board of Pediatrics, 2005
Alpha Omega Alpha The University of Chicago Pritzker School of Medicine, 2003
Medical Scientists Training Program The Univeristy of Chicago Pritzker School of Medicine, 1992
Join now to see all

Clinical Trials

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) Start of enrollment: 2011 Mar 04
Completed
Phase 1
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) Start of enrollment: 2012 Nov 20
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) Start of enrollment: 2013 Aug 28
Completed
Phase 3
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Start of enrollment: 2014 May 29
Completed
Phase 1, Phase 2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) Start of enrollment: 2014 Jul 15
Completed
Phase 1
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma Start of enrollment: 2014 Dec 08
Terminated
Phase 3
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Start of enrollment: 2015 Mar 18
Recruiting
Phase 1, Phase 2
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) Start of enrollment: 2015 Jul 16
Active, not recruiting
Phase 3
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Oct 15
Active, not recruiting
Phase 3
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) Start of enrollment: 2016 Jun 21
Completed
Phase 3
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) Start of enrollment: 2016 Jul 08
Active, not recruiting
Phase 1
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment Start of enrollment: 2017 Oct 03
Recruiting
Phase 2
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Start of enrollment: 2018 Jun 28
Terminated
Phase 2
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 3
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) Start of enrollment: 2018 Nov 19
Active, not recruiting
Phase 1
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Start of enrollment: 2019 Jan 31
Recruiting
Phase 4
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Start of enrollment: 2019 Jan 30
Active, not recruiting
Phase 2
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Start of enrollment: 2019 Mar 12
Active, not recruiting
Phase 3
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Active, not recruiting
Phase 2
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) Start of enrollment: 2020 Jun 26
Recruiting
Phase 1, Phase 2
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) Start of enrollment: 2020 Jun 26
Recruiting
Phase 1, Phase 2
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) Start of enrollment: 2020 Jul 01
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
Michele Maio, Matteo S. Carlino, Anthony M. Joshua, Elaine McWhirter, Antoni Ribas, Paolo A. Ascierto, Wilson H. Miller, Marcus O. Butler, Pier Francesco Ferrucci, Rob...> ;European Journal of Cancer. 2021 Nov 17
2 citations
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, Matteo S. Carlino, Tara C. Mitchell, Peter Hersey, Jacob Schachter, Georgina V. Long, F. Stephen Hodi, Jedd D. Wolchok, Ana Ara...> ;European Journal of Cancer. 2021 Nov 1
2 citations
Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
Chen Hu, Meihua Wang, Cai Wu, Heng Zhou, Cong Chen, Scott J. Diede> ;JAMA network open. 2021 May 3
18 citations
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey, Roxana S. Dronca...> ;European Journal of Cancer. 2021 Feb 1
34 citations
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Rosalie Step...> ;Journal for ImmunoTherapy of Cancer. 2020 Dec 1
5 citations
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Richard W. Joseph, Frank Xiaoqing Liu, Alicia C. Shillington, Cynthia Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Todd L. Saretsky, Alan S. Pickard> ;Quality of Life Research. 2020 May 13
27 citations
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediat...
Andrew D.J. Pearson, Claudia Rossig, G. Lesa, Scott J. Diede, Susan L. Weiner, John Anderson, Juliet C. Gray, Birgit Geoerger, Veronique Minard-Colin, Lynley V. Marsha...> ;European Journal of Cancer. 2020 Jan 24
85 citations
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim anal...
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Lynley V. Marshall, Catherine Vezina, Alberto S. Pappo, Theodore W. Laetsch, Antonio Sergio Petrilli, Martin Ebing...> ;Lancet Oncology. 2020 Jan 1
4 citations
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers
Richard W. Joseph, Alicia C. Shillington, Todd A. Lee, Cynthia Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Emilie Scherrer, Frank Xiaoqing Liu> ;Journal of Medical Economics. 2020 Feb 1
19 citations
Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
Frank Xiaoqing Liu, Wanmei Ou, Scott J. Diede, Eric D. Whitman> ;Medicine. 2019 Jul 1
336 citations
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, do...
Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean-Jacques Grob, Tae Min Kim, L...> ;Lancet Oncology. 2019 Aug 1
45 citations
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Ji-wei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. D...> ;Translational Oncology. 2019 Jun 1
21 citations
Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.
Eric D. Whitman, Frank Xiaoqing Liu, Xiting Cao, Scott J. Diede, Amin Haiderali, Amy P. Abernethy> ;Future Oncology. 2019 Feb 1
2 citations
Factors associated with immunotherapy selection in patients with advanced melanoma.
Richard W. Joseph, Alicia C. Shillington, Cynthia Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Frank Xiaoqing Liu> ;Immunotherapy. 2018 Nov 1
123 citations
Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (...
Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari M. Vanderwalde, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio...> ;Cell. 2018 Aug 9
21 citations
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Navin Pinto, Steven G. DuBois, Araz Marachelian, Scott J. Diede, Agne Taraseviciute, Julia L. Glade Bender, Denice D. Tsao-Wei, Susan Groshen, Joel M. Reid, Daphne A. ...> ;Pediatric Blood & Cancer. 2018 Jul 1
217 citations
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard W. Joseph, Roxana S...> ;Journal of Clinical Oncology. 2017 Dec 28
10 citations
Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart.
Takaaki Watanabe, Michael Marotta, Ryusuke Suzuki, Scott J. Diede, Stephen J. Tapscott, Atsushi Niida, Xiongfong Chen, Lila Mouakkad, Anna A. Kondratova, Armando E. Gi...> ;Cell Reports. 2017 Nov 21
175 citations
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari VanderWalde, Robert H I Andtbacka, Olivier Michielin, Anthony J Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fern...> ;Cell. 2017 Sep 7
27 citations
Spontaneous regression of metastatic cancer: learning from neuroblastoma.
Scott J. Diede> ;Nature Reviews Cancer. 2014 Jan 9
12 citations
Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer.
Scott J. Diede, Zizhen Yao, Christopher C. Keyes, Ashlee E. Tyler, Joyoti Dey, Christopher S. Hackett, Katrina Elsaesser, Christopher J. Kemp, Paul E. Neiman, William ...> ;Epigenetics. 2013 Oct 9
14 citations
Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles
Michael Marotta, Xiongfong Chen, Takaaki Watanabe, Pieter W. Faber, Scott J. Diede, Stephen J. Tapscott, Raymond R. Tubbs, Anna A. Kondratova, Robert M. Stephens, Hisa...> ;Nucleic Acids Research. 2013 Nov 1
1 citations
TERT hypermethylation: biomarker in paediatric brain tumours
Scott J. Diede> ;Lancet Oncology. 2013 May 1
45 citations
Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription F...
Kyle L. MacQuarrie, Zizhen Yao, Abraham P. Fong, Scott J. Diede, Erin R. Rudzinski, Douglas S. Hawkins, Stephen J. Tapscott> ;Molecular and Cellular Biology. 2013 Feb 15
41 citations
Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas.
Sarah E. Mahoney, Zizhen Yao, Christopher C. Keyes, Stephen J. Tapscott, Scott J. Diede> ;Epigenetics. 2012 Apr 1
Join now to see all